Answer
No, blinatumomab’s antitumour activity is polyclonal and independent of human leukocyte antigen (HLA) molecules on target cells.
Sources for this answer
- BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusionAmgen Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 26Document updated
Sources checked